Cabergoline in the treatment of Parkinson's disease;Cabergolina en el tratamiento de la enfermedad de Parkinson

Neurologia

Volumn 18, Issue 4, 2003, Pages 202-209

  Pastor, P ^a   Tolosa, Eduardo ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Cabergoline; Dopaminergic agonists; Parkinson's disease

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; ROPINIROLE;

ADJUVANT THERAPY; AKINESIA; ANXIETY DISORDER; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSKINESIA; DYSPEPSIA; DYSTONIA; EDEMA; GASTRITIS; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEADACHE; HUMAN; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; REVIEW; SLEEP DISORDER; VOMITING;

ANTIPARKINSON AGENTS; BRAIN; DRUG TOLERANCE; ERGOLINES; HUMANS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS;

EID: 0041671124     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Stocchi F. Dopamine agonists in Parkinson's disease: what is their role in early treatment? CNS Drugs 1998;10:159-70.
2. Cocchiara G, Benedetti MS. Excretion balance and urinary metabolic pattern of [3H]cabergoline in man. Drug Metabol Drug Interact 1992;10:199-211.
3. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 1997;48:363-8.
4. Benedetti MS, Dostert P, Barone D, Efthymiopoulos C, Peretti G, Roncucci R. In vivo interaction of cabergoline with rat brain dopamine receptors labelled with [3H]N-n-propylnorapomorphine. Eur J Pharmacol 1990;187:399-408.
5. Fariello RG. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs 1998;55(Suppl 1):10-6.
6. Grondin R, Goulet M, Di Paolo T, Bedard PJ. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res 1996;735:298-306.
7. Battaglia R, Strolin Benedetti M, Mantegani S, Castelli MG, Cocchiara G, Dostert P. Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica 1993;23:1377-89.
8. Fahn S, Elton RL, Committee MotUD. Unified Parkinson's disease Rating Scale. En: Fahn S, Marsden CD, Calne DB, et al., editors. Recent developments in Parkinson's disease. Vol 2. Florham Park (NJ): MacMillan Healthcare information 1987:153-63.
9. Jori MC, Franceschi M, Giusti MC, Canal N, Piolti R, Frattola L, et al. Clinical experience with cabergoline, a new ergoline derivative, in the treatment of Parkinson's disease. Adv Neurol 1990;53:539-43.
10. DA agonists-ergot derivatives: cabergoline: management of Parkinson's disease. Mov Disord 2002;17(Suppl 4):S68-71.
11. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55(Suppl 1):23-30.
12. Ahlskog JE, Wright KF, Muenter MD, Adler CH. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect. Clin Neuropharmacol 1996;19:202-12.
13. Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. Neurology 1996;46:1062-5.
14. Steiger MJ, El-Debas T, Anderson T, Findley U, Marsden CD. Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 1996;243:68-72.
15. Destee A, Schneider E, Gershanik O, Dom R, Tichy J, Korczyn AD. Efficacy and tolerability of cabergoline compared to bromocriptine in patients suffering from levodopa associated motor complications. (not on treatment with DA-agents). Mov Dis 1996;11 (Suppl 1):269.
16. Inzelberg R, Nisipeanu P, Rabey JM, Orlov E, Catz T, Kippervasser S, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology 1996;47:785-8.
17. Ulm G, Schüler P, MODAC Study Group. Cabergoline versus pergolide: a video-blinded, randomized, multicenter crossover study. Aktuel Neurol 1999;25:360-5.
18. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease. Eur Neurol 2001;46(Suppl 1):18-23.
19. Rinne UK, and the PKDS009 Collaborative Study Group. A five-year, double-blind study with cabergolina versus levodopa. Parkinsonism and Related Disorders 1999;5(Suppl):74.
20. Chaudhuri KR, Bhattacharya K, Agapito C, Porter MC, Mills J, Clough C. The use of cabergoline in nocturnal parkinsonian disabilities causing sleep disruption: A parallel study with controlled release levodopa. Eur J Neurol 1999;6(Suppl 5):S11-S15.
21. Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology 1993;43:2587-90.
22. Hutton JT, Morris JL, Brewer MA. Controlled study of the antiparkinsonian activity and tolerability of cabergoline. Neurology 1993;43:613-6.
23. Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, et al. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. Neurology 1993;43:1981-4.
24. Pal S, Bhattacharya KF, Agapito C, Chaudhuri KR. A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy. J Neural Transm 2001;108:71-7.
25. Bhatt MH, Keenan SP, Fleetham JA, Calne DB. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991;30:613-6.
26. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992;5:263-5.
27. Ling LH, Ahlskog JE, Munger TM, Limper AH, Oh JK. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease. Mayo Clin Proc 1999;74:371-5.
28. Appiah-Kubi L, Nisbet A, Burn D, J., Ray CK. Cabergoline monotherapy in clinical practice: A two year observational study of tolerability and efficacy in young, old and very elderly patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73:231.
29. Porter MC, Appiah-Kubf LS, Chaudhuri KR. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist. Int J Clin Pract 2002;56:468-74.
30. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology. Neurology 1998;50:S1-57.
31. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-3.
32. Hubble JP. Long-term studies of dopamine agonists. Neurology 2002;58:S42-50.